Datascope — Proxy Contest (November 2007)
31 slides from Datascope's proxy contest presentation, Nov 26, 2007
Slide 1: Schedule 14A
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box:
Slide 2: Presentation to Institutional Shareholder Services
On November 26, 2007, Datascope Corp. made the following presentation to Institutional Shareholder Services, a proxy advisory firm.
Slide 3: Investor Presentation
Investor Presentation November 26, 2007
Slide 4: Safe Harbor Statement / Additional Information
Safe Harbor Statement / Additional Information This presentation contains (and the comments made during this presentation may contain) forward-looking statements within the meaning of the Private Securities Litigation Reform Act. All statements that address expectations or projections about the futu
Slide 5: Agenda
Agenda Introduction About Datascope Strategic Plan Working to Drive Growth Datascope’s Current Board Is The Right Board Ramius’ Nominees: The Wrong Choice for Datascope Conclusion and Recommendation 3
Slide 6: Introduction
Introduction Datascope has a sound strategic plan working to drive sustainable and profitable growth Datascope’s Board and management are focused on growth while returning excess capital to shareholders Ramius is a short-term hedge fund that offers NO plan or vision to benefit Datascope Datascope ha
Slide 7: Datascope Overview
Datascope Overview Leading medical device company with diversified product portfolio reaching thousands of hospitals and customers globally Founded in 1964; Public company since 1972 Strong market position Global leader in intra-aortic balloon pump and catheter market for cardiac assist Worldwide re
Slide 8: Company Highlights
Company Highlights 35 years of consistent profitability and strong cash flow generation Net earnings growth in 27 years out of 35 years as public company Strong balance sheet Consistently shared earnings and cash flow with shareholders Since October 2004, paid approx. $91 million ($6.03 per share) i
Slide 9: Product and Geographic Operational Breakdown
Product and Geographic Operational Breakdown FY2007 Revenue by Segment FY2007 Revenue by Geography Interventional Vascular Products Products 4% 9% Rest of World 41% North America Patient 59% Monitoring 41% Cardiac Assist 46% 7
Slide 10: Financial Summary (Non-GAAP)
Financial Summary (Non-GAAP) Operating Income ($mm) Earnings Per Share $50 $2.00 ’05-’07 CAGR: 12% ’05-’07 CAGR: 6% $40 $1.60 $1.59 $1.50 $1.42 $34 $30 $1.20 $31 $27 $20 $0.80 $10 $0.40 $0 $0.00 FY2005 FY2006 FY2007 FY2005 FY2006 FY2007 *See reconciliation to GAAP results in appendix 8
Slide 11: Stock Performance
Stock Performance 5 Year Total Returns Indexed Price $200 $175 +72% +67% $150 $125 $100 $75 11/23/2002 5/8/2003 10/21/2003 4/4/2004 9/17/2004 3/2/2005 8/15/2005 1/28/2006 7/13/2006 12/26/2006 6/10/2007 11/23/2007 Datascope Total Return S&P 500 Total Return * Assumes reinvestment of dividends 9
Slide 12: Datascope has Consistently Returned Excess Free Cash Flow to Shareholders
Datascope has Consistently Returned Excess Free Cash Flow to Shareholders Since October 2004, Board has returned approx. $91 million ($6.03 per share) in quarterly cash and special dividends Includes $1.00 special dividend and regular dividend of $0.10 per share, both paid on 10/15/07 2.5 2 1.5 2.00
Slide 13: Strategic Plan Working to Drive Growth
Strategic Plan Working to Drive Growth Continuous expansion of innovative product portfolio Internal R&D Acquisitions and distribution agreements Leverage existing resources and product portfolio Cross-divisional utilization of resources Increase utilization of counterpulsation therapy Expand our pr
Slide 14: Investment in R&D is the Lifeblood of Datascope
Investment in R&D is the Lifeblood of Datascope In FY2007, Datascope introduced new products that address market opportunities, including: CS300TM Safeguard SensationTM 7 Fr. Spectrum OR Gas Module SE-Spirometry SpO2 Telepak New software products to increase functionality of Datascope’s Panorama cen
Slide 15: Expansion of Innovative Product Portfolio
Expansion of Innovative Product Portfolio Leadership position in Cardiac Assist market Sensation™ 7 Fr. fiber-optic balloon catheter High-fidelity optical blood pressure monitoring replaces conventional monitoring Smallest balloon catheter on the market Enables clinicians to deliver counterpulsation
Slide 16: Expansion of Innovative Product Portfolio (cont'd)
Expansion of Innovative Product Portfolio (cont’d) NetGuard™– Revolutionary new Clinical Alert System Announced in October 2007; Marketing launched in November 2007 Designed to protect unmonitored hospital population by detecting dangerous or life- threatening heart rhythm and notifying care-giver E
Slide 17: NetGuard – Revolutionary, New Clinical Alert System
NetGuardTM – Revolutionary, New Clinical Alert System TM Introducing NetGuard Coming soon to a hospital near you. NetGuard uniquely and economically monitors the electrical activity of the heart (ECG) in order to protect the unmonitored hospital patient population in the event of a life-threatening
Slide 18: Cross-Divisional and Expanded Utilization of Counterpulsation
Cross-Divisional and Expanded Utilization of Counterpulsation Greater integration Unified customer service Common approach to distributors markets Increase utilization of Counterpulsation Cardiogenic Shock is a class I indication for IABP therapy Less than 30% of Cardiogenic Shocks WW are treated Pr
Slide 19: Strategic Acquisitions and Investments
Strategic Acquisitions and Investments EVH enables less-invasive techniques for harvesting of suitable vessels for use in conjunction with Coronary Bypass Surgery EVH Datascope’s strength in cardiovascular surgery call points is highly Business synergistic with the EVH products 2006 Additional oppor
Slide 20: Strategic Acquisitions and Investments (cont'd)
Strategic Acquisitions and Investments (cont’d) Five-year license from the Sorin Group of Milan, Italy, for exclusive distribution of Sorin’s peripheral vascular stent products globally (except U.S. and Japan) Sorin Two-year option to purchase Sorin peripheral stent business 2007 Expected to grow ra
Slide 21: Growing Core Businesses and Divesting Non-Core Assets
Growing Core Businesses and Divesting Non-Core Assets Datascope Japan K.K. Wholly-owned subsidiary to manage IABP business in Japan Responsible for import, product service, sales support and product surveillance Appointed USCI Holdings Ltd., a premier medical device sales organization, to distribute
Slide 22: Strengthened Senior Management Team
Strengthened Senior Management Team Dr. Antonino Laudani, COO Created and headed EMEA* group Lawrence Saper Founder, Chairman and CEO Group’s sales increased 6% annually - 43 years Contribution to consolidated earnings grew Dr. Antonino Laudani VP, Chief Operating Officer 12% per year compounded - 5
Slide 23: Datascope's Board is the Right Board
Datascope’s Board is the Right Board Majority of Board is independent Board has right balance of tenure and skills Three new directors appointed to Board since 2003 Necessary depth and breadth of expertise: seasoned executives with more than 300 years of combined experience serving as leaders of pub
Slide 24: Datascope's Independent, Experienced Directors
Datascope’s Independent, Experienced Directors Directors Standing for Re-Election James J. Loughlin Financial expert as defined under SEC rules Audit Committee (C) Retired senior partner of KPMG (40-year career), led Life Science and Pharmaceuticals practices Compensation Committee Served as Chairma
Slide 25: Strong Corporate Governance
Strong Corporate Governance Respected, seasoned and proven business leaders who have a working understanding of medical devices and related industries Designated lead outside director Majority of independent directors All key committees comprised solely of independent directors Active and involved B
Slide 26: Ramius Offers Nothing
Ramius Offers Nothing Ramius is a short-sighted hedge fund that did not own a single share in Datascope until less than three months ago Short-term, opportunistic interests not aligned with those of all shareholders Distorts facts and findings of Audit Committee’s review: uninformed and misguided ac
Slide 27: Ramius' Nominees Are Not Qualified To Lead Datascope
Ramius’ Nominees Are Not Qualified To Lead Datascope Ramius nominees have little or no experience with Datascope’s business and targets Neither of Ramius’ nominees owns any Datascope stock Rubber Stamp: Nominees lack independence and represent only the interests of Ramius According to Ramius’ own pr
Slide 28: Setting the Record Straight
Setting the Record Straight Audit Committee Review: Facts have been fully disclosed in the Company’s SEC filings Audit Committee took immediate and appropriate actions to investigate anonymous allegations it received Assisted by independent counsel and forensic accountants selected by Audit Committe
Slide 29: Conclusion and Recommendation
Conclusion and Recommendation Datascope has a sound strategic plan working to drive sustainable and profitable growth Datascope’s Board and management are focused on growth while returning excess capital to shareholders Ramius is a short-term hedge fund that offers NO plan or vision to benefit Datas
Slide 30: Datascope - innovation is the best medicine
——_ Datascop innovation is the best medicine
Slide 31: Reconciliation of Adj. Net Income and Operating Profit to Reported
Reconciliation of Adj. Net Income and Operating Profit to Reported Net Income and Operating Profit For the Fiscal Year Ending, 2005 2006 2007 For the Fiscal Year Ending, 2005 2006 2007 Net Income, as reported $14.6 $25.8 $17.5 Operating Income, as reported $19.2 $29.3 $21.4 Adjustments for Special I